DOYLE; Anthony Gerard
Patent Applications and Registrations
Patent applications and USPTO patent grants for DOYLE; Anthony Gerard.The latest application filed is for "antibodies that specifically bind to human il-15 and uses thereof".
- DOYLE; Anthony Gerard - Macquarie Park AU
- Doyle; Anthony Gerard - Drummoyne AU
- DOYLE; Anthony Gerard - Park AU
- Doyle; Anthony Gerard - New South Wales AU
| Patent | Date |
|---|---|
| Antibodies That Specifically Bind To Human Il-15 And Uses Thereof App 20220127352 - LAINE; David Jose Simon ; et al. | 2022-04-28 |
| Antibodies that specifically bind to human IL-15 and uses thereof Grant 11,267,883 - Laine , et al. March 8, 2 | 2022-03-08 |
| Anti-par-2 Antibodies And Methods Of Use Thereof App 20220056125 - BRACKEN; Anna Mikaela ; et al. | 2022-02-24 |
| Combination of lenalidomide and polypeptide construct, and uses thereof Grant 11,253,591 - Pogue , et al. February 22, 2 | 2022-02-22 |
| Antibodies Against Tl1a And Uses Thereof App 20210347904 - POULTON; Lynn Dorothy ; et al. | 2021-11-11 |
| Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B Grant 11,117,975 - Clarke , et al. September 14, 2 | 2021-09-14 |
| Antibodies against TL1a and uses thereof Grant 10,822,422 - Poulton , et al. November 3, 2 | 2020-11-03 |
| Antibodies That Specifically Bind To Human Il-15 And Uses Thereof App 20200270339 - LAINE; David Jose Simon ; et al. | 2020-08-27 |
| Combination Of Lenalidomide And Polypeptide Construct, And Uses Thereof App 20190151447 - Pogue; Sarah L. ; et al. | 2019-05-23 |
| Combination of lenalidomide and polypeptide construct, and uses thereof Grant 10,232,041 - Pogue , et al. | 2019-03-19 |
| Anti-cd38 Antibodies And Fusions To Attenuated Interferon Alpha-2b App 20180305460 - Clarke; Adam ; et al. | 2018-10-25 |
| Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B Grant 9,963,515 - Clarke , et al. May 8, 2 | 2018-05-08 |
| Combination Of Lenalidomide And Polypeptide Construct, And Uses Thereof App 20170202962 - Pogue; Sarah L. ; et al. | 2017-07-20 |
| Combination of lenalidomide and polypeptide construct, and uses thereof Grant 9,636,334 - Pogue , et al. May 2, 2 | 2017-05-02 |
| Antibodies Against TL1a and Uses Thereof App 20160333104 - Poulton; Lynn Dorothy ; et al. | 2016-11-17 |
| Anti-il-12/il-23 Antibodies App 20160264661 - Clarke; Adam William ; et al. | 2016-09-15 |
| Anti-cd38 Antibodies And Fusions To Attenuated Interferon Alpha-2b App 20160068612 - Clarke; Adam ; et al. | 2016-03-10 |
| Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof App 20150313965 - Pogue; Sarah L. ; et al. | 2015-11-05 |
| ANTIBODIES TO CD1d App 20140286957 - Nambiar; Jonathan Kannan ; et al. | 2014-09-25 |
| ANTIBODIES AGAINST TL1a AND USES THEREOF App 20140255302 - Poulton; Lynn Dorothy ; et al. | 2014-09-11 |
| Anti-il-12/il-23 Antibodies App 20140086922 - Clarke; Adam William ; et al. | 2014-03-27 |
| Anti-IL-12/IL-23 antibodies Grant 8,563,697 - Clarke , et al. October 22, 2 | 2013-10-22 |
| Variant Domain Antibodies App 20110319597 - Simpson; Raina Jui Yu ; et al. | 2011-12-29 |
| Anti-il-12/il-23 Antibodies App 20110262445 - Clarke; Adam William ; et al. | 2011-10-27 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 